Kairos Ventures, a venture capital firm with ties to multiple academic institutions, hopes to raise $250m for its third main fund.

Kairos Ventures, a US-based venture capital firm focused on academic and industry innovation, is looking to raise $250m for its third main fund, according to a regulatory filing.
Founded in 2015, Kairos Ventures backs companies in the life sciences, physical sciences and technology spaces.
The firm typically supplies between $150,000 and $20m depending on the stage of investment, and also provides expertise and contacts.
Kairos’s earlier bets include Harvard University’s gene-editing technology developer Beam Therapeutics, Caltech-founded microbiome CNS drug business Axial Biotherapeutics and Columbia University’s wireless communications spinout MixComm.
The firm’s academic partnerships include a pact with Purdue Research Foundation, the university’s strategic affiliate, which grants access to Purdue-linked businesses during incubation and series A rounds.
Kairos Ventures’ second main fund, Kairos Venture Partners II, had raised $85m of its projected $150m target as of mid-2017, according to a filing.
The firm subsequently secured an initial $24.6m sum in June 2019 for a targeted $100m vehicle called Kairos Venture Opportunities.